First Epigenetic Reprogramming Therapy Enters Human Trials as Longevity Science Reaches a Clinical Turning Point
Life Biosciences began the first human trial of a cellular rejuvenation therapy using partial epigenetic reprogramming in Q1 2026, while senolytic pilot data shows safety in Alzheimer's-risk patients.
Overview
The field of longevity science reached a milestone in January 2026 when the FDA cleared Life Biosciences’ investigational new drug application for ER-100, a therapy that uses three Yamanaka transcription factors to partially reprogram the epigenetic state of aging cells without converting them back into stem cells. The Phase 1 trial, now underway, represents the first time a cellular rejuvenation therapy based on epigenetic reprogramming has entered human testing, targeting patients with open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy, according to Life Biosciences. The trial is registered as NCT07290244. In parallel, a multi-institutional pilot study published in eBioMedicine has produced the first human safety data for senolytic drugs in patients at risk for Alzheimer’s disease, finding that the combination of dasatinib and quercetin was well tolerated and correlated with reduced inflammation and improved cognition in the most impaired participants. Together, these developments signal that longevity research is transitioning from laboratory theory to clinical reality.
The Reprogramming Approach
Life Biosciences’ ER-100 delivers three of the four Yamanaka factors, OCT4, SOX2, and KLF4, known collectively as OSK, via a viral vector injected directly into the eye. The therapy is designed to restore youthful epigenetic patterns in retinal ganglion cells without triggering full dedifferentiation into pluripotent stem cells, a process that would risk tumor formation. Expression of the OSK genes is controlled by an antibiotic switch using doxycycline, allowing clinicians to activate and deactivate reprogramming as needed.
The approach builds on research demonstrating that aging is driven in part by the accumulation of epigenetic noise, chemical modifications to DNA that alter gene expression without changing the underlying genetic sequence. By resetting these modifications to a younger configuration, partial epigenetic reprogramming aims to restore cellular function. Comprehensive nonhuman primate studies conducted by Life Biosciences demonstrated “controlled OSK expression, restoration of methylation patterns, and improved visual function,” according to Sharon Rosenzweig-Lipson, the company’s chief scientific officer.
The Phase 1 trial will assess safety, tolerability, and immune responses in patients with optic neuropathies, with visual function assessments as secondary endpoints. The eye was chosen as the initial target because it is an immune-privileged organ that allows localized delivery, minimizing systemic exposure to reprogramming factors.
Senolytics Move Beyond Preclinical Promise
A separate line of longevity research is also reaching human testing. Researchers from Harvard Medical School, the Mayo Clinic, Cedars-Sinai Medical Center, and Beth Israel Deaconess Medical Center conducted a pilot study administering the senolytic combination of dasatinib (100 milligrams) and quercetin (1,250 milligrams) to 12 older adults with mild cognitive impairment and slow gait speed, both indicators of Alzheimer’s disease risk. The drugs were given on two consecutive days every two weeks for 12 weeks, an intermittent schedule based on preclinical evidence that senolytics destroy senescent cells without requiring continuous presence in the body.
The study, published in eBioMedicine, reported no serious adverse events. Common mild side effects included fatigue, poor sleep, and dizziness. The most notable finding was that reductions in tumor necrosis factor-alpha, a key inflammatory marker, were significantly and inversely correlated with increases in Montreal Cognitive Assessment scores. Participants with the lowest baseline cognitive scores showed a statistically significant 2.0-point improvement, suggesting that those most impaired may benefit most from senescent cell clearance.
The results are preliminary. The study had no control group and enrolled only 12 participants, making it impossible to rule out placebo effects or natural variation. A separate NIA-funded trial investigating senolytics for bone health in older women found only subtle benefits, underscoring that the translation from dramatic mouse-model results to meaningful human outcomes remains uncertain.
A Crowded and Well-Funded Field
Life Biosciences is not alone in pursuing cellular rejuvenation. Retro Biosciences, backed by OpenAI CEO Sam Altman, is pursuing a $5 billion valuation as it develops epigenetic editing, cell replacement therapies, and autophagy-boosting drugs with the stated goal of adding ten years to human lifespan, according to STAT News. Internal presentations reportedly describe longevity as “the greatest pharma market of all time.” Altos Labs, founded with $3 billion from investors including Yuri Milner, has also begun early human safety testing. NewLimit, co-founded by Coinbase CEO Brian Armstrong, is pursuing epigenetic reprogramming for immune system rejuvenation.
The global anti-aging market generated more than $85 billion in 2025, and projections place it near $120 billion by 2030. But the gap between investor enthusiasm and clinical evidence remains wide. No longevity-focused therapy has completed a pivotal trial demonstrating that it extends human healthspan, and the regulatory pathway for drugs that target aging itself, rather than a specific disease, remains undefined.
What Remains Unknown
Whether partial epigenetic reprogramming can be safely applied to tissues beyond the eye, where systemic delivery would expose the entire body to reprogramming factors, is the central unanswered question. The risk of incomplete reprogramming causing dysplasia or tumor formation has been observed in mouse studies and represents a fundamental safety concern that Phase 1 data alone will not resolve.
For senolytics, the question is whether intermittent clearance of senescent cells produces durable benefits. Senescent cells accumulate continuously throughout life, and whether periodic destruction alters the trajectory of age-related decline or merely provides temporary relief is unknown. The correlation between reduced TNF-alpha and improved cognition in the pilot study is promising but far from establishing a causal therapeutic mechanism.
Looking Ahead
The Life Biosciences trial will generate the first human safety data for epigenetic reprogramming, a dataset that every company in the longevity space will scrutinize. If ER-100 proves safe and shows visual function improvement in optic neuropathy patients, it would validate the core premise that aging-related epigenetic changes are reversible in living humans, a finding that would reshape drug development across multiple disease areas. The senolytic pilot data, meanwhile, provides enough signal to justify larger controlled trials, which multiple groups are now designing. For a field that has long been criticized for overpromising, 2026 is the year the evidence begins to accumulate.